Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein

Charles L. Groomes; David M. Gianferante; Gary D. Crouch; Dina S. Parekh; David W. Scott; Kenneth Lieuw

doi:10.1002/pbc.25874

Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein

Charles L. Groomes, David M. Gianferante, Gary D. Crouch, Dina S. Parekh, David W. Scott, Kenneth Lieuw^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

The development of inhibitors toward factor VIII (FVIII) is a common and serious complication of hemophilia A (HA) therapy. Patients with hemophilia who develop inhibitors often undergo time- and resource-intensive immune tolerance induction (ITI) protocols. We report a 15-month-old male with severe HA and a high-titer inhibitor that occurred while receiving prophylactic treatment with recombinant FVIII (rFVIII), in whom significant inhibitor titer reduction was achieved with thrice weekly infusions of a new, prolonged half-life rFVIII-Fc fusion protein product (trade name Eloctate). Further studies are warranted to explore the potential of Eloctate in ITI protocols.

Original language	English
Pages (from-to)	922-924
Number of pages	3
Journal	Pediatric Blood and Cancer
Volume	63
Issue number	5
DOIs	https://doi.org/10.1002/pbc.25874
State	Published - 1 May 2016
Externally published	Yes

Keywords

Eloctate
Factor VIII inhibitors
Hemophilia A
Immune tolerance induction
Recombinant factor VIII-Fc fusion protein

Access to Document

10.1002/pbc.25874

Cite this

@article{608d83b7f43f4eea964ea784d21b5813,

title = "Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein",

abstract = "The development of inhibitors toward factor VIII (FVIII) is a common and serious complication of hemophilia A (HA) therapy. Patients with hemophilia who develop inhibitors often undergo time- and resource-intensive immune tolerance induction (ITI) protocols. We report a 15-month-old male with severe HA and a high-titer inhibitor that occurred while receiving prophylactic treatment with recombinant FVIII (rFVIII), in whom significant inhibitor titer reduction was achieved with thrice weekly infusions of a new, prolonged half-life rFVIII-Fc fusion protein product (trade name Eloctate). Further studies are warranted to explore the potential of Eloctate in ITI protocols.",

keywords = "Eloctate, Factor VIII inhibitors, Hemophilia A, Immune tolerance induction, Recombinant factor VIII-Fc fusion protein",

author = "Groomes, {Charles L.} and Gianferante, {David M.} and Crouch, {Gary D.} and Parekh, {Dina S.} and Scott, {David W.} and Kenneth Lieuw",

note = "Publisher Copyright: {\textcopyright} 2016 Wiley Periodicals, Inc.",

year = "2016",

month = may,

day = "1",

doi = "10.1002/pbc.25874",

language = "English",

volume = "63",

pages = "922--924",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

number = "5",

}

TY - JOUR

T1 - Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein

AU - Groomes, Charles L.

AU - Gianferante, David M.

AU - Crouch, Gary D.

AU - Parekh, Dina S.

AU - Scott, David W.

AU - Lieuw, Kenneth

PY - 2016/5/1

Y1 - 2016/5/1

N2 - The development of inhibitors toward factor VIII (FVIII) is a common and serious complication of hemophilia A (HA) therapy. Patients with hemophilia who develop inhibitors often undergo time- and resource-intensive immune tolerance induction (ITI) protocols. We report a 15-month-old male with severe HA and a high-titer inhibitor that occurred while receiving prophylactic treatment with recombinant FVIII (rFVIII), in whom significant inhibitor titer reduction was achieved with thrice weekly infusions of a new, prolonged half-life rFVIII-Fc fusion protein product (trade name Eloctate). Further studies are warranted to explore the potential of Eloctate in ITI protocols.

AB - The development of inhibitors toward factor VIII (FVIII) is a common and serious complication of hemophilia A (HA) therapy. Patients with hemophilia who develop inhibitors often undergo time- and resource-intensive immune tolerance induction (ITI) protocols. We report a 15-month-old male with severe HA and a high-titer inhibitor that occurred while receiving prophylactic treatment with recombinant FVIII (rFVIII), in whom significant inhibitor titer reduction was achieved with thrice weekly infusions of a new, prolonged half-life rFVIII-Fc fusion protein product (trade name Eloctate). Further studies are warranted to explore the potential of Eloctate in ITI protocols.

KW - Eloctate

KW - Factor VIII inhibitors

KW - Hemophilia A

KW - Immune tolerance induction

KW - Recombinant factor VIII-Fc fusion protein

UR - http://www.scopus.com/inward/record.url?scp=84961230835&partnerID=8YFLogxK

U2 - 10.1002/pbc.25874

DO - 10.1002/pbc.25874

M3 - Article

C2 - 26739399

AN - SCOPUS:84961230835

SN - 1545-5009

VL - 63

SP - 922

EP - 924

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 5

ER -

Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein

Abstract

Keywords

Access to Document

Fingerprint

Cite this